Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario

Jacques P. Brown¹, Jonathan D. Adachi², Emil Schemitsch³, Jean-Eric Tarrière⁴,⁵,⁶, Vivien Brown⁷, Alan Bell⁷, Maureen Reiner⁸, Thiago Oliveira⁹, Ponda Motsepe-Ditshego⁹, Natasha Burke⁹ and Lubomira Slatkovska⁹*

Abstract

Background: Recent studies are lacking reports on mortality after non-hip fractures in adults aged > 65.

Methods: This retrospective, matched-cohort study used de-identified health services data from the publicly funded healthcare system in Ontario, Canada, contained in the ICES Data Repository. Patients aged 66 years and older with an index fragility fracture occurring at any osteoporotic site between 2011 and 2015 were identified from acute hospital admissions, emergency and ambulatory care using International Classification of Diseases (ICD)-10 codes and data were analyzed until 2017. Thus, follow-up ranged from 2 years to 6 years. Patients were excluded if they presented with an index fracture occurring at a non-osteoporotic fracture site, their index fracture was associated with a trauma code, or they experienced a previous fracture within 5 years prior to their index fracture. This fracture cohort was matched 1:1 to controls within a non-fracture cohort by date, sex, age, geography and comorbidities. All-cause mortality risk was assessed.

Results: The survival probability for up to 6 years post-fracture was significantly reduced for the fracture cohort vs matched non-fracture controls (p < 0.0001; n = 101,773 per cohort), with the sharpest decline occurring within the first-year post-fracture. Crude relative risk of mortality (95% confidence interval) within 1-year post-fracture was 2.47 (2.38–2.56) in women and 3.22 (3.06–3.40) in men. In the fracture vs non-fracture cohort, the absolute mortality risk within one year after a fragility fracture occurring at any site was 12.5% vs 5.1% in women and 19.5% vs 6.0% in men. The absolute mortality risk within one year after a fragility fracture occurring at a non-hip vs hip site was 9.4% vs 21.5% in women and 14.4% vs 32.3% in men.

Conclusions: In this real-world cohort aged > 65 years, a fragility fracture occurring at any site was associated with reduced survival for up to 6 years post-fracture. The greatest reduction in survival occurred within the first-year post-fracture, where mortality risk more than doubled and deaths were observed in 1 in 11 women and 1 in 7 men following a non-hip fracture and in 1 in 5 women and 1 in 3 men following a hip fracture.

Keywords: Fracture, Osteoporosis, Mortality, Real-world, Older adults
Background

The link between osteoporosis-related fragility fractures and mortality has been established by studies conducted across the globe over the last 3 decades, especially for hip fractures [1–10]. These studies show that in different countries with different types of healthcare systems, a fragility fracture was associated with a greater risk of mortality within the first year following the fracture and remained increased for several years after. Similar results have been reported in Canada [4, 7–10], whereby a fragility fracture occurring at any osteoporotic site increased mortality risk by 1.4–1.5-fold in adults aged 50 years and older [4]. When examining specific fragility fracture sites, a 2–4-fold mortality risk increase was observed after hip, vertebral or humerus (in men) fractures in Canadians aged 50 and older [4, 7, 8], while several other fracture sites were found to be associated with a 1.4–2-fold mortality risk increase (rib, humerus, forearm, or pelvic fracture in women; wrist fracture in men) [4, 8].

In spite of this mortality burden, a large gap currently exists for the primary prevention of fracture, and studies show that an estimated 80–90% of adults do not receive appropriate osteoporosis management even in the secondary prevention setting [11–13]. In contrast, approximately 90% of patients with cardiovascular disease are provided appropriate secondary preventive care [14]. System-level and country-level healthcare initiatives have been implemented worldwide to focus on addressing the secondary fracture prevention gap [15, 16], with several reports showing these initiatives being effective in not only reducing subsequent fragility fracture rates but also associated mortality [17–20]. Considering these data and the current fracture prevention gap, it is important to further improve knowledge of mortality associated with fragility fractures among medical or non-medical professionals involved in osteoporosis care [11–13, 21–23].

Studies examining post-fracture mortality after non-hip fractures over the past decade have typically focused on younger patient populations (aged ≥ 50 years), while studies examining mortality risk in adults aged > 65 have focused primarily on hip fractures [4, 7–10]. As such, there is a gap in understanding the mortality risks post fracture occurring at any or non-hip osteoporotic sites in adults aged > 65. Within this group, due to age-related fracture risk increase, more serious recommendations currently exist for fracture risk assessment or pharmacological intervention for osteoporosis [24, 25], and therefore the closing of the fracture prevention gap is that much more important.

The primary objective of this study was to utilize health services data from the publicly funded healthcare system in Canada to assess mortality post-fracture in a large, real-world cohort of adults aged > 65 years who experienced an index fragility fracture of any osteoporotic and non-hip site between 2011 and 2015, in comparison to matched non-fracture controls. Secondarily, surgeries and complications, which partly relate to mortality, were analyzed for all fragility fracture sites examined in this study.

Methods

Study design

A population-based retrospective matched-cohort study was conducted using public healthcare databases including health services records for about 13 million people living in Ontario, Canada. Primary databases used to identify and describe cases in this study were the Registered Persons Database (RPDB), Discharge Abstract Database (DAD), Same Day Surgery (SDS), National Ambulatory Care Reporting System (NACRS), and Ontario Health Insurance Plan (OHIP) (Supplementary Table 1). Healthcare encounters were recorded in multiple record-level, administrative datasets in the ICES Data Repository, and encrypted patient-specific identifiers (ICES-specific key number [IKN]) were used to link the administrative datasets.

Participants and setting

Included in the fracture cohort were Ontario residents aged 66 years and older (> 65) with an index fracture occurring at an osteoporotic fracture site from January 1, 2011 to March 31, 2015, identified from acute hospital admissions, emergency and ambulatory care using International Classification of Diseases (ICD)-10 diagnostic codes for fracture (Supplementary Table 2) as a main diagnosis or admitting diagnosis (ie, if no definite diagnosis was made, the main symptom, abnormal finding or problem was selected) [26]. Patients with fractures occurring at the following osteoporotic fracture sites were included in the fracture cohort: hip, vertebral (clinical), wrist (distal radius, or both distal radius and ulna), clavicle/sternum, rib, humerus, tibia/fibula/knee (including medial and lateral malleolus), pelvis, radius/ulna (proximal, midshaft, or distal ulna only), multisite, femur. Patients were excluded if they presented with an index fracture of non-osteoporotic fracture sites (ie, skull, face, hands, and feet) or their index fracture was associated with a trauma code (Supplementary Table 3) to maximize the probability that only fragility fractures were examined [9]. Patients were also excluded if they experienced a previous fracture during the 5-year look-back period prior to the index fracture date to minimize the likelihood that post index fracture mortality was influenced by a recent fracture occurring prior to an index event.

Patients in the fracture cohort were matched 1:1 to controls (non-fracture cohort) from the Registered Persons Database (RPDB) who did not experience a fracture
between January 1, 2011 and March 31, 2015 or during the 5-year lookback period prior to their index date. Matching was performed based on the following a priori specified variables: month and year of index date (random index date assigned to controls); sex; age groups (66–70, 71–75, 76–80, 81–85, ≥86 years); geography (rural/urban); and comorbidities (respiratory conditions: asthma, chronic obstructive pulmonary disorder [COPD]; inflammatory conditions: rheumatoid arthritis, psoriasis, spondylarthritis; cancer within 5 years; chronic kidney disease; diabetes; vascular events: myocardial infarction, stroke and cerebrovascular events; dementia; and osteoarthritis).

Data were analysed from the index date until March 31, 2017 (Supplementary Fig. 1). Index date was defined as the date of the index fracture in the fracture cohort and the date of when the follow-up was initiated in the non-fracture cohort. Thus, depending on the index date, the opportunity for follow-up ranged between 2 years (2015–2017) and 6 years (2011–2017). Data from 5 years prior to the index date were also collected to describe clinical characteristics in both cohorts.

Study size
The fracture cohort included all Ontario residents who experienced a fragility fracture that were registered in the DAD/SDS and NACRS using the above-specified criteria for osteoporotic fracture sites and non-trauma fractures, and were able to be matched to the non-fracture controls using the above-specified matching criteria (see Participants and setting section). Both sets of criteria were specified a priori to minimize selection bias. The cohort was limited to those aged 66 years and older (>65) to collect medication data based on public drug coverage for at least 1 year prior to the index fracture. The 2011–2015 index period was selected to allow at least 2 years of follow-up post-index date and was based on data availability in the ICES Data Repository when the data collection started in 2018.

Variables and data sources
Identifying mortality
Deaths occurring due to any cause from the index date until end of the study period were obtained from the RPDB for both fracture and non-fracture cohorts.

Identifying fracture-related surgeries and complications
Fracture-related orthopedic surgical procedures (initial and revision) were assessed from the date of index fracture until the end of follow-up in the fracture cohort using the DAD/SDS and Canadian Classification of Health Interventions (CCI) codes (Supplementary Table 4), and surgery-related complications were assessed up to 30 days after an index event using the DAD / SDS, NACRS, and OHIP databases based on ICD-9 or 10 codes (Supplementary Table 5). Vertebroplasty and balloon kyphoplasty were not included in the analysis of fracture-related orthopedic surgical procedures, because these procedures are typically not performed as part of the standard initial orthopedic management of vertebral fractures, as their primary aim is to minimize complications associated with severe and/or multiple vertebral fractures (kyphosis). For deaths and surgical procedures, a minimum follow-up of 1 year was required, but longer follow-up was permitted.

Identifying fractures
Index and second fragility fractures occurring during the follow-up period were examined in the fracture cohort using the DAD/SDS for inpatient visits and NACRS for emergency and ambulatory visits. For the second fragility fractures, the same criteria were applied to examine fractures occurring at osteoporotic sites without trauma as for the index fractures (see Participants and setting section). Fracture of the same site that was dated within 91 days of the index fracture was assumed to stem from the same fracture and was not counted as a second fracture [27]. The anatomical location of multisite index fracture was used to exclude a subsequent single-site fracture occurring in a similar location within 91 days.

Identifying clinical characteristics
The following databases were used to assess clinical characteristics at the time of the index date in the fracture and non-fracture cohort: RPDB for age and sex; Ontario Drug Benefit (ODB) for medications; and DAD/SDS, NACRS, OHIP, Ontario Rheumatoid Arthritis Administrative Database, Ontario Cancer Registry, Ontario Renal Reporting System, Ontario Diabetes Database, Ontario Myocardial Infarction Database, ASTHMA, COPD for comorbidities using the ICD-9 or ICD-10 codes where applicable.

Statistical methods
Cumulative proportions of deaths due to any cause within 1, 2 or 3 years after an index fracture occurring at any site (fracture cohort) or start of follow-up (non-fracture cohort) were calculated separately for women and men and expressed as absolute risks and absolute risk differences (fracture cohort – non-fracture cohort). Crude relative risks were calculated for women and men (fracture cohort/non-fracture cohort). Adjustment for confounders was not deemed necessary in light of these large cohorts being matched on many a priori specified potential confounders. Survival analysis was conducted using Kaplan-Meier estimates with log rank statistics for evaluation of statistical significance for comparisons between the fracture and non-fracture cohorts.
Cumulative proportions of deaths due to any cause within 1, 2 or 3 years after index fracture were further stratified for fracture cohort participants by hip vs non-hip fracture site and by age categories (66–70, 71–75, 76–80, 81–85, 86+ years). For each fracture site, proportions of deaths, fracture-related surgeries or complications within 1 year were calculated.

**Results**

**Clinical characteristics**

A total of 115,776 eligible adults (72.3% female) > 65 years sustained an index fragility fracture between January 1, 2011 and March 31, 2015. From the full, unmatched cohort of 115,776 adults with fragility fracture a subset of 101,773 (88%) were able to be matched 1:1 with non-fracture controls based on a priori specified variables including index date, age category, sex, geography and comorbidities (Fig. 1). All clinical characteristics used for matching were similar between the matched fracture and non-fracture cohorts (Table 1). Mean age ($p = 0.04$) and osteoporotic medication use 1 year prior to the index date (any, bisphosphonates, denosumab, or raloxifene; $p < 0.001$) were statistically different between the matched cohorts (Table 1); these two characteristics were however not used for matching and the difference in each was small and deemed not clinically relevant. The full unmatched and matched fracture cohorts had similar clinical characteristics and proportions of different index and subsequent fractures sites (Table 1; Supplementary Table 6).

Within the fracture cohort, fractures occurring at the hip, wrist, humerus, and rib were the four most common fractures, representing approximately two thirds of index or second fracture sites (Table 1). Index hip fractures
alone represented 26.5% of index fractures ($n = 26,963$). By the end of follow-up (maximum 6 years), a second fracture of any site occurred in 17.6% ($n = 17,958$) of the fracture cohort, while a second hip fracture occurred in 4.9% ($n = 4956$). The median length of study follow-up was 3.26 years or 1190 days (Supplementary Table 7).

Survival analyses demonstrated a statistically significant difference in survival probability ($p < 0.0001$) between the fracture and non-fracture cohort over 6 years of follow-up (Fig. 2). Visual inspection of the Kaplan-Meier curve for the fracture cohort revealed a sharp initial drop in the proportion of individuals alive within 1-year post-index fracture. The curve continued to further separate from the non-fracture cohort over the remaining 5 years of follow-up, albeit not as steeply. Survival

### Table 1 Clinical characteristics of the fracture cohort and non-fracture cohorts

| Clinical Characteristics | Fracture cohort n (%) | Non-fracture cohort n (%) |
|--------------------------|-----------------------|---------------------------|
| **Total number of patients** | 101,773 | 101,773 |
| **Sex** | | |
| Female | 74,557 (73.3%) | 74,557 (73.3%) |
| Male | 27,216 (26.7%) | 27,216 (26.7%) |
| **Age** | | |
| Mean ± SD | 80.25 ± 8.37* | 80.33 ± 8.75* |
| Median (IQR) | 81 (73–87) | 81 (73–87) |
| 66–70 years | 16,672 (16.4%) | 16,672 (16.4%) |
| 71–75 years | 15,996 (15.7%) | 15,996 (15.7%) |
| 76–80 years | 17,952 (17.6%) | 17,952 (17.6%) |
| 81–85 years | 20,584 (20.2%) | 20,584 (20.2%) |
| ≥86 years | 30,569 (30.0%) | 30,569 (30.0%) |
| **Urban Residence** | | |
| Urban | 89,696 (88.1%) | 89,696 (88.1%) |
| Rural | 12,077 (11.9%) | 12,077 (11.9%) |
| **Respiratory conditions** | | |
| Asthma | 13,113 (12.9%) | 13,113 (12.9%) |
| COPD | 25,991 (25.5%) | 25,991 (25.5%) |
| **Inflammatory conditions** | | |
| Rheumatoid arthritis | 2208 (2.2%) | 2208 (2.2%) |
| Psoriasis | 4985 (4.9%) | 4985 (4.9%) |
| Spondyloarthritis | 2432 (2.4%) | 2432 (2.4%) |
| **Cancer** | | |
| 5166 (5.1%) | 5166 (5.1%) |
| **Chronic kidney disease** | | |
| 8909 (8.8%) | 8909 (8.8%) |
| **Diabetes** | 29,074 (28.6%) | 29,074 (28.6%) |
| **Vascular events** | | |
| Myocardial infarction | 4549 (4.5%) | 4549 (4.5%) |
| Stroke or cerebrovascular events | 28,015 (27.5%) | 28,015 (27.5%) |
| **Osteoarthritis** | 77,526 (76.2%) | 77,526 (76.2%) |
| **Dementia** | 18,359 (18.0%) | 18,359 (18.0%) |
| **Osteoporosis treatment type within 1 year prior** | | |
| Any treatment | 28,974 (28.5%) | 21,179 (20.8%) |
| Denosumab | 1383 (1.4%) | 1088 (1.1%) |
| Bisphosphonate | 25,626 (25.2%) | 17,720 (17.4%) |
|Raloxifene | 999 (0.6%) | 255 (0.5%) |
|HRT | 3259 (3.2%) | 2117 (2.0%) |
| **Index fracture by site** | | |
| Hip | 26,963 (26.5%) | – |
| Wrist | 16,467 (16.2%) | – |
| Humerus | 11,756 (11.6%) | – |
| Ribs | 10,247 (10.1%) | – |
| Tibia/fibula/knee | 9859 (9.7%) | – |
| Pelvis | 7209 (7.1%) | – |
| Vertebral | 6595 (6.5%) | – |

### Table 1 Clinical characteristics of the fracture cohort and non-fracture cohorts (Continued)

| Clinical Characteristics | Fracture cohort n (%) | Non-fracture cohort n (%) |
|--------------------------|-----------------------|---------------------------|
| Radius/ulna | 4377 (4.3%) | – |
| Multisite | 3299 (3.2%) | – |
| Femur | 2618 (2.6%) | – |
| Clavicle/sternum | 2383 (2.3%) | – |
| Any site | 101,773 (100%) | – |

**Values reported as n (%) unless otherwise indicated: percent of total respective cohort**

* $p < 0.05$, ** $p < 0.001$ statistical significance between fracture cohort and non-fracture cohort

*Variable not used for matching

*Time frame for cancer was 5 years within index data and for all other comorbidities any time prior to index date

*Within 1 year of index date. Bisphosphonates include alendronate, cyclical etidronate, risedronate, or zoledronic acid. Denosumab is not publicly covered in men and teriparatide in men or women in Ontario

*Index fragility fracture cases from January 1, 2011 to March 31, 2015. Second fragility fracture cases from the date of index event to March 31, 2017. Reported from highest to lowest number
probability (95% CI) in the fracture vs non-fracture cohorts was 85.6% (85.4–85.9%) vs 94.7% (94.5–94.8%) within 1-year post-fracture and 58.5% (58.1–58.9%) vs 75.2% (74.9–75.6%) within 5 years post-fracture. The following cumulative proportions of patients died over the three year post-fracture period in the fracture-cohort and the non-fracture cohort: 14.4% (n = 14,617) and 5.3% (n = 5418) in year 1; 21.5% (n = 21,854) and 10.5% (n = 10,676) in year 2, and 28.4% (n = 28,952) and 15.6% (n = 15,849) in year 3.

The absolute risk of death was significantly greater in women and men in the fracture cohort vs non-fracture cohort (Table 2). At 1, 2 and 3 years post index date, the absolute risk difference was, respectively, 7.4% (95% CI 7.1–7.7%), 9.1% (95% CI 8.7–9.4%) and 10.8% (95% CI 10.4–11.2%) in women and 13.5% (95% CI 12.9–14.0%), 16.2% (95% CI 15.5–16.8%) and 18.5% (95% CI 17.7–19.2%) in men. Within 1, 2 and 3 years post-index date, the unadjusted relative risk was, respectively, 2.47 (95% CI 2.38–2.56), 1.92 (95% CI 1.87–1.97), and 1.73 (95% CI 1.70–1.77) in women and 3.22 (95% CI 3.06–3.40), 2.34 (95% CI 2.26–2.43) and 2.04 (95% CI 1.98–2.10) in men. The absolute risk of death was 1.4–1.6x higher in men vs women with fractures over the three years post-fracture, and 1.2x higher in men vs women without fractures.

**Mortality after index fractures stratified by age or fracture site**

In women, the range for the absolute risk of death observed between the youngest (66–70) and oldest (86+) age groups at year 1, 2, and 3 was, respectively, 3.5–23.6%, 5.3–34.9%, and 7.3–45.8% (Table 2), representing 6.3–6.7-fold difference between the youngest and oldest groups. The absolute risk of death in women with vs without fractures aged 66–70, 71–75, 76–80, 81–85, 86+ years, respectively, was higher by 3.6–, 3.1–, 2.7–, 2.4–, and 2.3-fold at year 1; 2.6–, 2.5–2.1–, 1.9–, and 1.8-fold at year 2; and 2.2–, 2.2–, 1.9–, 1.7–, and 1.7-fold at year 3. In men, the range for the absolute risk of death observed between the youngest (66–70) and oldest (86+) age group at year 1, 2, and 3 was, respectively, 6.9–34.6%, 10.9–48.6%, and 14.5–59.8%, representing 4.1–5.0-fold difference between the youngest and oldest groups. The absolute risk of death in men with vs without fractures aged 66–70, 71–75, 76–80, 81–85, 86+ years, respectively, was higher by 4.9–, 3.7–, 3.9–, 3.0–, and 2.9-fold at year 1; 3.6–, 2.9–, 2.6–, 2.2–, and 2.1-fold at year 2; and 2.8–, 2.5–, 2.3–, 1.9–, and 1.8-fold at year 3. Compared to women with fractures, the absolute risk of death over the three years post-fracture was 1.7–2.1x higher in men aged 66–85 years. This relative difference between sexes declined in the oldest, 86+ age group and was 1.3–1.5x higher in men vs women. This age-sex trend was also present in the non-fracture cohort, with 1.4–1.7x higher mortality rate in men vs women aged 66–85 years and 1.2x in those aged 86+ over the three years post-index date.

The absolute risk of death in women (all ages) with hip fracture, with non-hip fracture and without fracture was, respectively, 21.5–39.0%, 9.4–20.9% and 5.1–14.8% over the three years post-index date, and 32.3–52.9%, 14.4–29.6% and 6.0–17.8% in men (all ages) (Table 2). The absolute risk of death in women 1) with hip
Table 2 Absolute risk of death and number of deaths in the fracture cohort and the non-fracture cohort

| Mortality          | Fracture cohort       | Non-fracture cohort       |
|--------------------|-----------------------|--------------------------|
|                    | Female (N = 74,557)   | Male (N = 27,216)        |
|                    | Number of deaths (%)  | Number of deaths (%)     |
| Within 1 year      | 9306 12.5 (12.2, 12.7)| 5311 19.5 (19.0, 20.0)  |
| 66–70 years        | 410 3.5 (3.2, 3.8)    | 340 6.9 (6.2, 7.7)       |
| 71–75 years        | 588 5.2 (4.8, 5.6)    | 501 10.7 (9.8, 11.7)     |
| 76–80 years        | 1007 7.8 (7.3, 8.3)   | 835 16.5 (15.4, 17.7)    |
| 81–85 years        | 1739 11.6 (11.1, 12.2)| 1226 21.9 (20.7, 23.1)  |
| 86+ years          | 5562 23.6 (22.9, 24.2)| 2409 34.6 (33.3, 36.0)  |
| Hip index fracture  | 4126 21.5 (20.8, 22.1)| 2499 32.3 (31.3, 33.6)  |
| Non-hip index fracture | 5180 9.4 (9.1, 9.6)| 2812 14.4 (13.9, 15.0)  |
| Within 2 years     | 14,171 19.0 (18.7, 19.3)| 7683 28.2 (27.6, 28.9)  |
| 66–70 years        | 628 5.3 (4.9, 5.8)    | 539 10.9 (10.0, 11.9)    |
| 71–75 years        | 936 8.3 (7.7, 8.8)    | 757 16.2 (15.1, 17.4)    |
| 76–80 years        | 1605 12.4 (11.8, 13.1)| 1207 23.9 (22.5, 25.2)  |
| 81–85 years        | 2771 18.5 (17.8, 19.2)| 1801 32.1 (30.7, 33.7)  |
| 86+ years          | 8231 34.9 (34.1, 35.6)| 3379 48.6 (47.0, 50.3)  |
| Hip index fracture  | 5784 30.1 (29.3, 30.9)| 3322 43.0 (41.5, 44.4)  |
| Non-hip index fracture | 8387 15.2 (14.8, 15.5)| 4361 22.4 (21.7, 23.1)  |
| Within 3 years     | 19,084 25.6 (25.2, 26.0)| 9868 36.3 (35.5, 37.0)  |
| 66–70 years        | 852 7.3 (6.8, 7.8)    | 716 14.5 (13.5, 15.6)    |
| 71–75 years        | 1290 11.4 (10.8, 12.0)| 989 21.2 (19.9, 22.5)    |
| 76–80 years        | 2276 17.7 (16.9, 18.4)| 1605 31.7 (30.2, 33.3)  |
| 81–85 years        | 3862 25.8 (25.0, 26.6)| 2396 42.7 (41.1, 44.5)  |
| 86+ years          | 10,804 45.8 (44.9, 46.6)| 4162 59.8 (58.0, 61.7)  |
| Hip index fracture  | 7495 39.0 (38.1, 39.9)| 4094 52.9 (51.3, 54.6)  |
| Non-hip index fracture | 11,589 20.9 (20.6, 21.3)| 5774 29.6 (28.9, 30.4)  |

*Percent of the total respective subgroup by age category or hip / non-hip fracture site

fractures vs without fractures, 2) with non-hip fractures vs without fractures, and 3) with hip vs non-hip fracture, respectively, was higher by 4.2-, 1.9-, and 2.3-fold at year 1, 3.0-, 1.5-, and 2.0-fold at year 2, and 2.6-, 1.4-, and 1.9-fold at year 3. The absolute risk of death was 1.4–1.5x higher in men vs women with hip fractures over the three years post-fracture, and it was also 1.4–1.5x higher in men vs women with non-hip fractures. In terms of the contribution to the total number of mortality cases in the fracture cohort, hip fractures contributed 45.3% (n = 6625) of the total number of deaths within one year post-fracture.
Compared to 1-year absolute risk of death observed in the non-fracture cohort (5.3%), wrist (4.4%), radius/ulna (6.0%), and tibia/fibula/knee (5.8%) index fracture cases had similar mortality rates (Table 3). Femur (20.2%), multisite (18.4%), pelvis (18.0%) and vertebral (17.9%) index fractures were associated with the highest 1-year mortality rate following hip fracture (24.6%). In terms of the highest contribution to the total number of mortality cases, hip, rib, pelvis and vertebral index fractures together contributed 79.3% (n = 11,592) of the total number of deaths within one year post-fracture.

### Surgeonies and complications by index fracture site

Within the fracture cohort, 38.5% of adults required an index fracture-related surgical procedure, of which 7.8% had revision surgeries, and 19.0% experienced postsurgical complications (Table 3). Index fracture sites of the hip, femur and multisite were associated with the highest proportion of fracture cohort patients undergoing initial surgical procedures (91.4, 81.1 and 43.1%), experiencing complications (21.5, 34.7 and 19.4%), as well as dying within 1-year post-fracture (24.6, 20.2 and 18.4%).

### Discussion

This study of adults aged > 65 confirms that a fragility fracture of any site is associated with increased mortality risk [4]. Survival declined over 1–6 years post-fracture with the steepest reduction occurring within the first year, when the crude relative risk was 2.47- and 3.22-fold higher in matched fractured vs non-fractured women and men, respectively. Absolute mortality risk within 1-year post-fracture was 12.5% in women with fractures and 19.5% in men with fractures, with a large absolute risk difference when compared to matched non-fracture controls of 7.4% (95% CI 7.1–7.7%) in women and 13.5% (95% CI 12.9–14.0%) in men.

To add context to the 1-year absolute mortality risk of 14.4% post-index fracture at any site observed in our fracture cohort of women and men (50% aged ≥81), a 1-year absolute mortality risk of 9.7% was observed post-index acute myocardial infarction in Canadians admitted to a hospital between 2006 and 2010 (22% aged 65–74, 35% aged ≥75) [28]. When considering stroke-related mortality, an absolute mortality risk of 14.9% was reported at discharge in Canadians hospitalised due to ischemic stroke between 2003 and 2004 (aged ≥70, 55% aged > 80) [29]. Furthermore, an absolute mortality risk of 14.9% was observed within 30 days in-hospital in Canadians admitted to hospital with any stroke in 2012 (25% aged 70–79, 38% aged ≥80) [30]. Considering that significant reductions in mortality risks associated with cardiovascular events have been reported over the past few decades [30–32], this data demonstrating a clear association between fragility fracture and mortality risk further highlights the need for effective measures to improve osteoporosis management and prevention of fragility fractures in older adults [11–13, 17–19, 21–23].

Only one study published over the last decade examined mortality post-fragility fracture at any osteoporotic site in Canadians [4, 7–10]. This study of the prospective CaMos cohort (N = 7689; 72% women) which was...
younger (mean age 66 and IQR 59–73 years) than our cohort observed age-adjusted hazard ratios (95% CI) of 1.43 (1.24–1.64) and 1.42 (1.12–1.79) in fractured women and men, respectively [4]. The higher relative mortality risk increase post-fracture observed in our cohort compared to the CaMos cohort was likely partly driven by the higher number of hip fractures in our older cohort, since hip fracture numbers increase in older individuals. The mortality rate observed in our cohort was approximately 2-fold higher in hip fracture compared to non-fracture cases in both women and men over the three years post-fracture. However, non-hip fractures also contributed to increased mortality rate observed for all fractures combined, considering the 1.4–1.9- and 1.7–2.4-times greater mortality rate observed, respectively, in women and men with non-hip fracture vs no fracture. Data on non-hip fracture mortality rates in similar cohorts is lacking; however, the 1-year hip fracture mortality rate of 21.5% in women and 32.3% in men observed in our cohort was relatively similar to a 2013 Canadian cohort study of adults aged ≥ 65 which observed a 1-year hip fracture mortality rate of 22% in women and 33% in men [9]. Although not as common as hip fracture, femur, multisite, pelvis and vertebral fractures were also associated with relatively high 1-year mortality rate in this cohort compared to other fracture sites. Prior studies conducted in similar cohorts have also reported significantly increased mortality after pelvis and vertebral fractures [4, 7, 8].

The relative difference in mortality rate between fracture and non-fracture cases was observed to decline with increasing age in both women and men, although it remained approximately 2-3x higher even in women and men aged 86+ years. This age-related trend was also observed in prior research and has been attributed to younger adults having much lower absolute mortality rates and as such the excess mortality discrepancy between the younger and older groups may reflect the life expectancy gap in the general population [33]. Alternatively, younger individuals who experience fragility fracture at younger age may have a poorer health status for their age, compared to older individuals with fragility fractures [33]. The latter explanation calls for urgency to prevent fragility fractures in younger populations, however, further research is needed to help elucidate this age discrepancy.

Gender trends in our study showed that, although men made up about one-quarter of index fracture cases, they contributed to about one-third of deaths. Although the mortality rate was also higher in men vs women in the non-fracture cohort, this gender difference was slightly larger in the fracture cohort for all fractures combined, hip fractures or non-hip fractures. Compared to women, Canadian men were also previously observed to have significantly higher mortality risk after hip [8, 9], vertebral [4, 7, 8], and humerus fractures [4, 8]. Interestingly, the range in absolute mortality rate based on age was found to be wider in women with approximately 6–7-fold difference between the oldest and youngest age groups compared to men with approximately 4–5-fold difference. Perhaps younger men with fragility fracture may be more vulnerable than older men when compared to women of their respective age groups, or alternatively older women approach closer to older men in terms of their vulnerability. Although we observed a higher relative risk difference in mortality rate between women and men of younger age groups compared to older age groups, this observation was not unique to the fracture cohort. Further, research examining mortality rate post-fracture and interactions between sex and age is needed to help confirm and elucidate these observations.

Strengths of this study include having examined large fracture and non-fracture cohorts closely matched on age, sex, geography and comorbidities. A hard match method was used due to the limited number of covariates that were deemed important from a clinical point of view, and 88% of the full unmatched cohort was closely matched with the non-fracture cohort on these covariates. The matched fracture cohort was also similar to the full unmatched fracture cohort, supporting the generalizability of the findings of the matched analysis. Real-world data was captured through all fracture care-related public healthcare services from a province contributing to over one-third of fractures nationally [34]. Estimates of mortality risks in Canadian adults were reported as up to date, with previous studies relying on 1986–2013 data [4, 7–10]. Finally, Canadians aged > 65 were examined, who based on age alone are recommended for fracture risk assessments due to their age-related fracture risk [24], but have not been the focus of prior non-hip fracture mortality studies [4, 7–10].

Limitations of this study include the potential for residual confounding which always exists in any observational study, even after yielding a good match in our study based on a number of clinically relevant potential confounders. Another limitation stems from estimating crude mortality risks without adjusting for potential confounders that could not be used during matching, such as a number of and/or time to second fracture, which was previously found to be associated with increased mortality risk [6]. By excluding patients from the fracture cohort who had another fracture 5 years prior to their index event, but not beyond those 5 years, the fracture cohort was potentially biased towards an older population; this resulted in a mean age roughly 5 years higher than expected for adults aged > 65 [35]. By excluding patients from the non-fracture cohort who experienced a fracture 5 years prior to their index date, but
not beyond those 5 years, the non-fracture cohort might have included a small proportion of fractured patients. There may be an underestimation of the number of fractures in this cohort, particularly non-hip, considering that only the ‘Most Responsible Diagnosis (ie, if no definite diagnosis was made, the main symptom, abnormal finding, or problem was selected)’[26] and ‘Pre-Admit Comorbidity’ were used to identify index fractures. Vertebral fractures were likely underestimated considering that two-thirds are typically silent and that ‘Most Responsible Diagnosis’ was used to identify index fractures [36, 37]. Vertebral fractures could also be more thoroughly identified using the Wright et al. [27] algorithm which takes into account imaging codes in addition to fracture diagnosis codes. As in prior healthcare database research, the determination of fragility fracture was based on the exclusion of high-trauma ICD codes and not independent adjudication [9], which may have under/overestimated the number of fragility fractures in this cohort. Cause of death was unavailable and represents an opportunity for further research. Finally, while these results may be generalizable to populations similar to that of Ontario, there may be less generalizability to specific race and ethnic groups [27].

Conclusion
In this large, real-world cohort of Canadian adults aged > 65 years, a fragility fracture at any site was associated with reduced survival up to 6 years post-fracture, with the greatest reduction occurring within the first year, when mortality risk more than doubled. Within the first year, deaths were observed in 1 in 8 women and 1 in 5 men following any fracture, in 1 in 11 women and 1 in 7 men following a non-hip fracture, and in 1 in 5 women and 1 in 3 men following a hip fracture.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12891-021-03960-z.

Acknowledgements
This study made use of de-identified data from the ICES Data Repository, managed by the ICES with support from its funders and partners: Canada’s Strategy for Patient-Oriented Research (SPOR), the Ontario SPOR Support Unit, the Canadian Institutes of Health Research and the Government of Ontario. The opinions, results, and conclusions reported are those of the authors. No endorsement by ICES or any of its funders or partners is intended or should be inferred. Parts of this material are based on data and information compiled and provided by CIHI. However, the analyses, conclusions, opinions and statements expressed herein are those of the author, and not necessarily those of CIHI. Medical writing assistance was provided by Khalid Siddiqui from Amaris Consulting UK Ltd. and Kyle Wills from Amaris Conseil Inc., and funded by Amgen. The authors would like to thank Arpat Chabra and Erika Martire for their data summary support on the manuscript.

Authors’ contributions
JPB, JDA, ES, J-ET, VB, AB, MR, TO, PM-D, NB, and LS contributed to design of the study, review and interpretation of the data, and drafting and review of the manuscript.

Funding
This study was funded by Amgen Canada Inc. including design of the study and analysis and interpretation of data. Data collection was performed by ICES and sponsored by Amgen Canada Inc. Medical writing support was sponsored by Amgen Canada Inc.

Availability of data and materials
The data that support the findings of this study are available from ICES but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available [https://www.ices.on.ca/Data-and-Privacy/ICES-data] [38]. Data are however available from the authors upon reasonable request and with permission of ICES.

Ethics approval and consent to participate
The study protocol was approved by the Advarra Institutional Review Board. De-identified aggregate level data was provided from ICES following patient-level analysis.

Consent for publication
Not applicable.

Competing interests
JPB has received consulting fees and honoraria from Amgen and Servier; received research funding from Mereo BioPharma, Radius Health and Servier; served on speakers’ bureau for Amgen. JDA has received consulting fees from Amgen and Eli Lilly; received research funding from Amgen, Pfizer, and BMS; served on the ‘speakers’ bureau’ for Amgen; served on boards for the International Osteoporosis Foundation and Ontario Rheumatology Association. ES has received consulting fees from Amgen. J-ET has received consulting fees, research funding and honoraria from Allergan, AstraZeneca, Amgen, CSL Behring, Janssen, Novo Nordisk, Sage, Assurex/Myriad, Edwards Lifesciences, Pfizer, Roche, Merck, GlaxoSmithKline, Evidera, PCDI, CADTH. VB has received honoraria from Amgen and have served on Amgen Ad Boards. AB has received consulting fees, research funding and honoraria from Amgen, Bristol Myers Squibb, Janssen, AstraZeneca, Novartis, Pfizer, Bayer, Lilly, Boehringer Ingelheim, Sanofi, Valeant. LS, NB, PM-D, TO and MR are employees of and own stock in Amgen.

Author details
1CHU de Québec Research Centre and Laval University, Québec, QC, Canada. 2Department of Medicine, McMaster University, Hamilton, ON, Canada. 3Division of Orthopaedic Surgery, Western University, London, ON, Canada. 4Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, ON, Canada. 5Programs for Assessment of Technology in Health, The Research Institute of St. Joe’s Hamilton, St Joseph’s Healthcare Hamilton, Hamilton, ON, Canada. 6Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, ON, Canada. 7Department of Family and Community Medicine, University of Toronto, Toronto, Canada. 8Amgen Inc, California, USA. 9Amgen Canada Inc., Toronto, Canada.

Additional file 1: Supplementary Table 1. Primary databases used for the study. Supplementary Table 2. Diagnosis Codes for Frailty Fractures. Supplementary Table 3. Diagnosis Codes for Trauma Fractures. Supplementary Table 4. CCI codes for fragility fracture-related surgical technique procedures. Supplementary Table 5. Diagnosis codes for fragility fracture-related complications. Supplementary Table 6. Clinical characteristics of the full, unmatched fracture cohort. Supplementary Table 7. Index fragility fractures by age and calendar year. Supplementary Figure 1. Study schema.

Abbreviations
CI: Confidence interval; CCI: Canadian Classification of Health Interventions; COPD: Chronic obstructive pulmonary disorder; DAD: Discharge Abstract Database; ICD: International Classification of Diseases; IKMN: ICES-specific key number; NACRS: National Ambulatory Care Reporting System; OHIP: Ontario Health Insurance Plan; RPDB: Registered Persons Database; SDS: Same Day Surgery
References

1. Cooper C, Atkinson EJ, Jacobson SJ, O’Fallon WM, Melton LJ 3rd. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993;137(9):1001–5.

2. Klop C, van Staa TP, Cooper C, Harvey NC, de Vries F. The epidemiology of mortality after fracture in England: variation by age, sex, geographic location, and ethnicity. Osteoporos Int. 2017;28(1):161–8.

3. Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Perry DC, Willett K, et al. Populations-wide impact of non-hip non-vertebral fractures on mortality. J Bone Miner Res. 2017;32(9):1802–10.

4. Tran T, Blinc D, van Geel T, Adachi JD, Berger C, van den Bergh J, et al. Population-wide impact of non-hip non-vertebral fractures on mortality. J Bone Miner Res. 2017;32(9):1802–10.

5. Center JR, Nguyen TV, Milch VE, Nguyen TD, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353(9156):878–82.

6. Blinc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301(5):513–21.

7. Ioannidis G, Papaioannou A, Chopman WM, Akhtar-Danesh N, Anastasiades T, Pickard L, et al. Relation between fractures and mortality: results from the Canadian multicentre osteoporosis study. CMAJ. 2009;181(5):265–71.

8. Morin S, Lix LM, Astrame M, Metge C, Caetano P, Leslie WD. Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int. 2011;22(9):4349–58.

9. Nikitovic M, Wodchis WP, Krahn MD, Cadarette SM. Direct health-care costs attributed to hip fractures among seniors: a matched cohort study. Osteoporos Int. 2013;24(2):659–69.

10. Pincus D, Ravi B, Wassermann D, Huang A, Paterson JM, Nathens AB, et al. Association between frailty and mortality in adults undergoing hip fracture surgery. JAMA. 2017;318(20):1994–2003.

11. Papaioannou A, Giangregorio L, Kvern B, Boulou P, Ioannidis G, Adachi JD. The osteoporosis care gap in Canada. BMC Musculoskelet Disord. 2004;5:11.

12. Bessette L, Ste-Marie LG, Jean S, Davison KS, Beaulieu M, Barani M, et al. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int. 2008;19(1):79–86.

13. Papaioannou A, Kennedy CC, Ioannidis G, Gao Y, Sawka AM, Goltzman D, et al. The osteoporosis care gap in men with fragility fractures: the Canadian multicentre osteoporosis study. Osteoporos Int. 2008;19(4):581–7.

14. Bell A, Hill MD, Herman RJ, Girard M, Cohen E. Canadian RoACHSRC. Management of atherothrombotic risk factors in high-risk Canadian outpatients. Can J Cardiol. 2009;25(6):345–51.

15. Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLeenan A, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012;27(10):2039–46.

16. Mitchell PJ. Best practices in secondary fracture prevention fracture liaison services. Curr Osteoporos Rep. 2013;11(1):52–60.

17. Huntjens VM, van Geel TC, Oseus PP, Winkens B, Willems P, van den Bergh J, et al. Impact of guideline implementation by a fracture nurse on subsequent fractures and mortality in patients presenting with non-vertebral fractures. Injury. 2011;42(Suppl 4):L39–43.

18. Hawley S, Jawad MK, Prieto-Alhambra D, Lippett J, Sheard S, Arden NK, et al. Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study. Age Ageing. 2016;45(2):236–42.

19. Metcalfe D, Zogok KK, Judge A, Perry DC, Gabbe B, Willett K, et al. Pay for performance and hip fracture outcomes: an interrupted time series and difference-in-differences analysis in England and Scotland. Bone Joint J. 2019;101-B(10):1015–23.

20. Gonzalez-Quevedo D, Bautista-Enrique D, Perez-Del-Rio V, Bravo-Bardajar M, Garcia-de-Quevedo D, Tamimi F. Fracture liaison service and mortality in elderly hip fracture patients: a prospective cohort study. Osteoporos Int. 2020;31(1):77–84.

21. Binkley N, Blank RD, Leslie WD, Leveeck EM, Eisman JA, Bilezianki JP. Osteoporosis in crisis: it’s time to focus on fracture. J Bone Miner Res. 2017;32(1):1391–4.

22. Dreinhofer KE, Mitchell PJ, Begue T, Cooper C, Costa ML, Falaschi P, et al. A global call to action to improve the care of people with fragility fractures. Injury. 2018;49(8):1393–7.

23. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019; 393(10169):364–76.

24. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010;182(17):1864–73.

25. Kanis JA, Cooper C, Rizzoli R, Registries J, Scientific advisory Board of the European Society for C, economic aspects of O, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44.

26. Canadian Institute for Health Information. Canadian Coding Standards for Version 2015 ICD-10-CA and CCI. 2015.

27. Wright NC, Daigle SG, Melton ME, DeZell ES, Balasubramanian A, Curtis JR. The design and validation of a new algorithm to identify incident fractures in administrative claims data. J Bone Miner Res. 2019;34(10):1798–807.

28. Talgi N, Ferguson TW, Whitlock RH, Rigatto C, Jassal DS, Kars M, et al. Long term health outcomes in patients with a history of myocardial infarction: a population based cohort study, PLos One. 2017;12(7):e0180010.

29. Saposnik G, Cote R, Phillips S, Gubitz G, Bayer N, Minuk J, et al. Stroke outcome in those over 80: a multicenter cohort study across Canada. Stroke. 2008;39(8):2310–7.

30. Kannel N, Lindsay MP, Cote R, Fang J, Kapral MK, Hill MD. Ten-year trends in stroke admissions and outcomes in Canada. Can J Neurol Sci. 2015;42(3):168–75.

31. Bata IR, Gregor RD, Wolf HK, Brownell B. Trends in five-year survival of patients discharged after acute myocardial infarction. Can J Cardiol. 2006;22(5):399–404.

32. Tu JV, Khan AM, Ng K, Chu A. Recent temporal changes in atherosclerotic cardiovascular diseases in Ontario: clinical and health systems impact. Can J Cardiol. 2017;33(3):378–84.

33. Blinc D, Center JR. Determinants of mortality risk following osteoporotic fractures. Curr Opin Rheumatol. 2016;28(4):413–9.

34. Osteoporosis Canada. Make the first break the last with Fracture Liaison Services: Appendix B: Fracture incidence and costs by province. 2013 [Available from: https://osteoporosescanada.ca/wp-content/uploads/FLS-TOOLKIT-AppB.pdf].

35. Beaudoin C, Jean S, Moore L, Garnache P, Bessette L, Ste-Marie LG, et al. Number, location, and time since prior fracture as predictors of future fracture in the elderly from the general population. J Bone Miner Res. 2018;33(11):1956–66.

36. Cooper C, Atkinson EJ, O’Fallon WM, Melton LJ 3rd. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992;7(2):221–7.

37. Ross PD. Clinical consequences of vertebral fractures. Curr Opin Cardiol. 2017;33(3):378–84.

38. ICES. ICES data 2020 [Available from: https://www.ices.on.ca/Data-and-Privacy/ICES-data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedicalcentral.com/submissions